STAT News

STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk

When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.

By STAT News

1 min read
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights